The FDA has approved supplemental New Drug Applications for three type 2 diabetes medicines within the empagliflozin family to include...
Empagliflozin (Jardiance®), a potent, highly selective, sodium glucose cotransporter-2 (SGLT2) inhibitor, is an effective and generally well tolerated antihyperglycaemic agent approved for the treatment of adults with type 2 diabetes (T2D) in the EU, USA and Japan, among other parts of the world.
Full results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, showed that empagliflozin was associated with a significant 25 percent relative risk reduction in the primary endpoint of time to cardiovascular death or hospitalization due to heart failure.
Objective: To examine whether lowering plasma glucose concentration with the sodium-glucose transporter-2 inhibitor empagliflozin improves β-cell function in patients with type 2 diabetes mellitus (T2DM).
Boehringer Ingelheim and Eli Lilly and Company announced that empagliflozin met the primary efficacy endpoint, defined as a change from...
The FDA has approved Synjardy (empagliflozin + metformin hydrochloride) tablets, from Boehringer Ingelheim and Eli Lilly, for the treatment of...
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
A study aimed to determine the safety and effectiveness of empagliflozin (Jardiance) in insulin-treated type 1 diabetes (T1D) patients. This...